Zobrazeno 1 - 10
of 15
pro vyhledávání: '"D. Mark Hickinson"'
Autor:
Donald Ogilvie, Robert W. Wilkinson, Bernard Barlaam, Paul Smith, Konstantina Grosios, Elizabeth Mills, Rowena Callis, Sara Davenport, Gayle Marshall, Sarah Beck, Judith Anderton, Cath Trigwell, John Vincent, Georgina Speake, Teresa Klinowska, D. Mark Hickinson
Supplementary Data from AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a7713f65d79a8772a0aabd9ebd0f375
https://doi.org/10.1158/1078-0432.22442994
https://doi.org/10.1158/1078-0432.22442994
Autor:
Donald Ogilvie, Robert W. Wilkinson, Bernard Barlaam, Paul Smith, Konstantina Grosios, Elizabeth Mills, Rowena Callis, Sara Davenport, Gayle Marshall, Sarah Beck, Judith Anderton, Cath Trigwell, John Vincent, Georgina Speake, Teresa Klinowska, D. Mark Hickinson
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and erbB3 receptor signaling, using the novel small-molecule inhibitor AZD89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc3df99d9418da872c459a0c2702594c
https://doi.org/10.1158/1078-0432.c.6519609.v1
https://doi.org/10.1158/1078-0432.c.6519609.v1
Autor:
Caroline Dive, Tim P. Green, D. Mark Hickinson, Richard A. Bryce, Heinz Bönisch, Christopher Smith, Mohammad Ghattas, Christopher J. Morrow
Elevated Src family kinase (SFK) activity is associated with tumor invasion and metastasis. The SFK inhibitor saracatinib (AZD0530) is currently in phase II trials in patients including those with colorectal cancer (CRC), where links between SFK acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5b3f6515e37c5ea91fa89a355c98fbc
https://doi.org/10.1158/0008-5472.c.6500564
https://doi.org/10.1158/0008-5472.c.6500564
Autor:
Caroline Dive, Tim P. Green, D. Mark Hickinson, Richard A. Bryce, Heinz Bönisch, Christopher Smith, Mohammad Ghattas, Christopher J. Morrow
Supplementary Figures 1-3, Table 1 from Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dcc0dc0322ee3901e12f5b0a3ed70cf
https://doi.org/10.1158/0008-5472.22383506
https://doi.org/10.1158/0008-5472.22383506
Autor:
Robert Hugh Bradbury, Cath Trigwell, John Vincent, Barlaam Bernard Christophe, Donald J. Ogilvie, George Kirk, Judith Anderton, Jason Grant Kettle, D. Mark Hickinson, Laurent Francois Andre Hennequin, Peter Ballard, Teresa Klinowska, Christine Lambert-van der Brempt
Publikováno v:
ACS Medicinal Chemistry Letters. 4:742-746
Deregulation of HER family signaling promotes proliferation and tumor cell survival and has been described in many human cancers. Simultaneous, equipotent inhibition of EGFR-, HER2-, and HER3-mediated signaling may be of clinical utility in cancer se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa7f05bc63b1a8fbb191a888276a0ce
https://doi.org/10.1021/ml400146c
https://doi.org/10.1021/ml400146c
Autor:
Gayle Marshall, John Vincent, Elizabeth A. Mills, Konstantina Grosios, Sarah Beck, Robert W. Wilkinson, Judith Anderton, Teresa Klinowska, Paul Smith, Georgina Speake, Sara Davenport, Cath Trigwell, Rowena Callis, D. Mark Hickinson, Donald J. Ogilvie, Barlaam Bernard Christophe
Publikováno v:
Clinical Cancer Research. 16:1159-1169
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human epidermal growth factor receptor 2), and erbB3 receptor signaling, using the novel small-molecule inhibitor AZD89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea88ad21570dbeaab661f48c2cdb30d1
https://doi.org/10.1158/1078-0432.ccr-09-2353
https://doi.org/10.1158/1078-0432.ccr-09-2353
Autor:
Barlaam Bernard Christophe, Jason Grant Kettle, Kevin Hudson, Cath Trigwell, James S. Scott, Peter Ballard, Françoise Magnien, Michel Vautier, Richard Ducray, Annie Olivier, D. Mark Hickinson, Teresa Klinowska, Stuart E. Pearson, Robin D. Whittaker, Donald J. Ogilvie, Abid Suleman, Robin Wood, Robert Hugh Bradbury, Hervé Germain
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:674-678
Starting from initial lead 1 containing a basic 5-substituent, optimisation of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compounds 19 and 21 inhibited phosphorylation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17b3f74bc73d8411112df955cbf4ab04
https://doi.org/10.1016/j.bmcl.2007.11.052
https://doi.org/10.1016/j.bmcl.2007.11.052
Autor:
Rémy Morgentin, Peter Ballard, D. Mark Hickinson, Laurent Francois Andre Hennequin, Johnson Paul David, Donald J. Ogilvie, Robert Hugh Bradbury, Teresa Klinowska, Jason Grant Kettle, Annie Olivier
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 15:4226-4229
Starting from a 6,7-substituted quinazoline lead 4, optimisation of 5-substituted quinazolines containing an extended aniline motif led to potent and selective inhibitors of erbB2 receptor tyrosine kinase, and a representative compound 12a inhibited
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96829569526116303bbf291985fb43e9
https://doi.org/10.1016/j.bmcl.2005.06.068
https://doi.org/10.1016/j.bmcl.2005.06.068
Autor:
D. Mark Hickinson, L Jackson, Zoe Howard, Robert W. Wilkinson, Neil H. James, Anna Wainwright, K Ratcliffe, Kerry L Acheson, Susan Lovick, Simon T. Barry, Rajesh Odedra, Georgina Speake, Neil R. Smith, Anderson J. Ryan, Sandra R. Brave, Dawn Baker, Gayle Marshall
Publikováno v:
International Journal of Oncology.
Vandetanib is a multi-targeted receptor tyrosine kinase inhibitor that is in clinical development for the treatment of solid tumours. This preclinical study examined the inhibition of two key signalling pathways (VEGFR-2, EGFR) at drug concentrations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2e27c441a4fe8eb994d461ab4f45ea7
https://doi.org/10.3892/ijo.2011.1022
https://doi.org/10.3892/ijo.2011.1022
Autor:
Georgina Speake, D. Mark Hickinson, Barry R. Davies, Robert W. Wilkinson, Alan Swaisland, Gayle Marshall, Yuri Rukazenkov, Judith Anderton
Publikováno v:
Anti-cancer drugs. 20(10)
Two small-molecule epidermal growth factor receptor tyrosine kinase inhibitors, gefitinib and erlotinib, have been approved for the treatment of non-small-cell lung cancer. Here, we compare the pharmacology and pharmacokinetics of these agents, and r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd189424d9ee3daeb2d384aa3c86a234
https://pubmed.ncbi.nlm.nih.gov/19657272
https://pubmed.ncbi.nlm.nih.gov/19657272